Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)


Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)

Seattle Genetics (NASDAQ: SGEN) reported second-quarter revenue and earnings numbers, but the conference call focused mostly on potential near-term revenue growth for the biotech's one approved drug, Adcetris, with one expanded indication under review at the FDA and another to be there shortly.

Metric

Q2 2017

Continue reading


Source: Fool.com

Seagen Inc. Stock

€210.40
-0.850%
The price for the Seagen Inc. stock decreased slightly today. Compared to yesterday there is a change of -€1.800 (-0.850%).

Like: 0
Share

Comments